Skip to main content
Figure 4 | Arthritis Research & Therapy

Figure 4

From: CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'

Figure 4

Baseline CXCL13 stratified by clinical disease activity score (+/-DAS28-remission) after 2 years of therapy. Both treatment groups are considered together. Bars represent median with IQR. *Indicates statistically significant difference (P = 0.03). CXCR13: C-X-C chemokine receptor type 13; DAS28: disease activity score in 28 joints; IQR: interquartile range.

Back to article page